Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
No Data
WW Transcript
WW International, Inc. (WW) Q1 2026 Earnings Call Transcript
Unknown5-11
Despite growth in clinical subscriptions and high ARPU, the 10% revenue decline and adjusted EBITDA loss are concerning. Positive impacts from new oral medications and a strong gross margin are offset by a decrease in cash reserves and a flat outlook for behavioral subscribers. The Q&A reveals strategic plans but lacks immediate catalysts for significant stock movement. Overall, mixed signals suggest a neutral stock reaction.
WW International, Inc. (WGHTQ) Q4 2025 Earnings Call Transcript
Unknown3-16
The earnings call highlights mixed results: strong clinical subscriber growth and increased ARPU, but a decline in behavioral subscribers and total revenue. Management's optimistic outlook on demand for new products and demographic expansion is positive, but lack of specific guidance and declining cash reserves pose concerns. The Q&A reveals positive sentiment towards new member growth and partnerships, yet vague responses on financial projections create uncertainty. Overall, the mixed signals and cautious market sentiment suggest a neutral stock price movement.
WW International, Inc. (WW) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents mixed signals. While clinical subscriber growth and strategic partnerships, including one with Amazon, are positive, the decline in revenue and behavioral subscribers is concerning. The company's financial health appears stable, with a significant reduction in term loan and cash reserves increase. However, uncertainties in the clinical business and lack of specific guidance on influencer campaign returns temper optimism. The market may react cautiously, resulting in a neutral stock price movement over the next two weeks.
WW International, Inc. (WW) Q2 2025 Earnings Call Transcript
Unknown8-11
The earnings call reveals several concerning factors: declining total subscribers, revenue headwinds, and challenges in transitioning Clinical members away from compounded semaglutide. Despite some positive financial metrics, such as debt reduction and ARPU growth, the overall sentiment is negative due to revenue decline, subscriber loss, and lack of clear guidance on future strategies. The Q&A section highlights competitive pressures and the absence of detailed plans for addressing challenges, further contributing to the negative outlook.
WW Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
